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Introduction
Ten years after the introduction of biologics in children,
we assess the tolerance of these therapies among patients
with juvenile idiopathic arthritis (JIA) in pediatric rheu-
matology centers.
Objectives
Study the epidemiology of JIA in 10 european centers of
pediatric rheumatology and describe adverse events
(AEs) to biologics at short and medium term.
Methods
Multicenter retrospective observational study in JIA
patients who have been treated with biologics, in the 10
following pediatric rheumatology centers: Basel, Zurich,
Aarau, Lucerne, Vaud (Switzerland), Lyon, Paris, Cler-
mont-Ferrand, Strasbourg (France) and Leuven (Bel-
gium) between June 1999 and March 2014.
Results
531 patients were included in the study. Most of them suf-
fered from polyarticular JIA (PA) RF negative (21.4 %, n =
115) . Other JIA subtypes were distributed as follow:
arthritis with enthesitis 19.3% (n= 102), oligoarticular JIA
(OA) persistent 17.4% (n= 92), systemic JIA 16.6% (n= 88),
OA JIA extent 10.6% (n= 56), psoriatic arthritis and JIA
PA RF positive 5.1% (n= 27) and other arthritis 4.5%. Ocu-
lar involvement was found in all subtypes of JIA except for
polyarticular FR+ consisting of 105 patients of which
19.8% (n=70) with positivity for antinuclear antibodies.
Familial history of autoimmunity was identified in more
than a quarter of cases (n=146, 27.6 %). A macrophage
activation syndrome (MAS) was found in 20 patients,
restricted to the systemic JIA subset.
Etanercept was the most common drug and accounted
for 47.5 % of all biologics in the cohort. Most of AEs
were mild, one third of AEs were due to reversible reac-
tions at the injection (such as rash, fever and pain). Infec-
tions represented one third of the AEs and were more
frequently secondary to viral agents. Tocilizumab was
more often involved in AEs with a frequency of 0.27 AE
patients/year, followed by infliximab and canakinumab
with 0.17 AE patients/year. No AE was seen with rituxi-
mab but this drug represented an overall exposition of
7,7 patients/year. Severe AEs were found in 19 patients
(3.4%) including two cases of Hodgkin’s disease. The
mean exposure duration to biologics at the first occur-
rence of AEs was 14.4 months. No deaths were reported.
Conclusion
This multicenter study shows an overall good tolerance
of JIA patients to biologics. The main AE are repre-
sented by infectious agents and preventive strategies
including vaccination should apply. Notably, 2 cases of
malignancy, both Hodgkin disease, were identified in the
cohort. The prospective follow-up of children treated
with biologics, and international efforts, such as Phar-
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